HTG Molecular Diagnostics Inc, Tucson, Ariz, has received Australian patent number 2,012,316,129 for “methods of codetecting mRNA and small noncoding RNA.
The technology claimed in the patent involves multiplexed nuclease-protection methods of detecting messenger RNA (mRNA) and small noncoding RNA, such as microRNA (miRNA), in a single test or assay. The patent provides protection until September 2032, and is part of a family of patents protecting the method, including a US patent issued in December 2016.
TJ Johnson, HTG Molecular Diagnostics.
“We are pleased to strengthen our intellectual property protection with the addition of this Australian patent covering this application of our core technology,” says TJ Johnson, chief executive officer of HTG. “We believe miRNAs are gaining relevance as possible diagnostic markers, and are very pleased to have our methods of mRNA and miRNA codetection patented in multiple geographies. We have consistently sought to protect uses of our technology in the United States and globally, and now have more than 20 patents covering our nuclease-protection-based technologies, including our HTG EdgeSeq method.”
For more information, visit HTG Molecular.
